سعر سيردوليكت 12 مجم 28 قرص 2024

Serdolect 12 mg is a Lundbeck sertindole film-coated tablet (pack of 28) marketed in Egypt through Multipharma; sertindole is a limbic-selective antipsychotic for schizophrenia, reserved for patients intolerant to at least one other antipsychotic because of QT-prolongation risk.

• Treatment of schizophrenia in patients intolerant to at least one other antipsychotic agentPopulation: AdultsHealth Products Regulatory Authority (HPRA), Ireland

• Very common: rhinitis/nasal congestion, ejaculation failure. Common: weight gain, dizziness, paraesthesia, peripheral oedema, prolonged QT interval, postural hypotension, dyspnoea, dry mouth, ejaculation disorder, erectile dysfunction, red/white blood cells in urine. Uncommon: hyperprolactinaemia, hyperglycaemia, syncope, convulsion, tardive dyskinesia, Torsade de Pointes, galactorrhoea. Rare: neuroleptic malignant syndrome.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland

• Hypersensitivity to sertindole or excipients; known uncorrected hypokalaemia or hypomagnesaemia.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland
• History of clinically significant cardiovascular disease, congestive heart failure, cardiac hypertrophy, arrhythmia or bradycardia (<50 beats/min); do not initiate in congenital long QT syndrome (or family history) or known acquired QT prolongation (QTc >450 ms in males, >470 ms in females).International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland
• Concomitant drugs that significantly prolong the QT interval (e.g. class Ia/III antiarrhythmics, thioridazine, erythromycin, terfenadine, astemizole, gatifloxacin, moxifloxacin, cisapride, lithium).International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland

• Prolongs the QT interval more than some other antipsychotics (greater at 20-24 mg); QT prolongation is associated with Torsade de Pointes and sudden death. Use only in patients intolerant to at least one other antipsychotic and comply fully with required safety measures.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland
• Postural hypotension may occur during initial titration because of alpha1-blocking activity.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland
• Fluoxetine, paroxetine and other potent CYP2D6 inhibitors may raise sertindole levels 2-3-fold; use only with extreme caution, possibly at a lower dose, with ECG monitoring; caution in known CYP2D6 poor metabolisers.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland

• QT-prolonging drugs (e.g. quinidine, amiodarone, sotalol, thioridazine)Additive QT prolongation; co-administration is contraindicated.Health Products Regulatory Authority (HPRA), Ireland
• Potent CYP3A inhibitors (e.g. ketoconazole, itraconazole, erythromycin, clarithromycin, indinavir, diltiazem, verapamil)May significantly increase sertindole levels, especially in CYP2D6 poor metabolisers; contraindicated.Health Products Regulatory Authority (HPRA), Ireland
• Potent CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine)Increase sertindole plasma levels 2-3-fold; use only with extreme caution, lower dose and ECG monitoring.Health Products Regulatory Authority (HPRA), Ireland

• Safety in pregnancy not established; not teratogenic in animals but reduced offspring fertility in rats at therapeutic-range doses; sertindole should not be used during pregnancy.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland
• No studies in nursing mothers, but sertindole is expected to be excreted in breast milk; if treatment is necessary, discontinuation of breastfeeding should be considered.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland

• Sertindole: Proposed to act through selective inhibition of mesolimbic dopaminergic neurons with balanced inhibitory effects on central dopamine D2 and serotonin 5-HT2 receptors and on alpha1-adrenergic receptors; no effect on muscarinic or histamine H1 receptors.